Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest gout Stories

2012-04-05 10:24:46

ISELIN, N.J., April 5, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today provided an update on the ongoing clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a proof-of-concept trial is being conducted at the Duke Clinical Research Unit of Duke University and the principal investigator is John Sundy, MD, PhD an expert in the treatment of gout. The trial is designed to assess the safety and efficacy of...

2012-03-05 07:00:00

EAST BRUNSWICK, N.J., March 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that KRYSTEXXA®(pegloticase) is now available in the European Union to healthcare professionals and their patients suffering from refractory chronic gout (RCG) through a Named Patient Programme, which is sponsored by its wholly-owned subsidiary, Savient Pharma Ireland Limited, and managed by Idis Limited (Idis). RCG is a difficult-to-treat form of gout and currently there are...

2012-02-17 15:34:00

ISELIN, N.J., Feb. 17, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2011. These results are included in the Company's Yearly Report on Form 10-K which has been filed with the SEC. Fourth Quarter Ended December 31, 2011 The Company recorded a net loss of $0.4 million, or $0.01 per share, for the fourth quarter 2011 compared to a net loss of $0.2 million, or $0.00 per share, in the...

2012-01-24 11:11:33

A daily dose of skimmed milk, enriched with two components found in dairy products, may help to curb the frequency of painful gout flare-ups, indicates research published online in the Annals of the Rheumatic Diseases. Previous long term research has shown that the risk of gout is greater among those whose diet is low on dairy products. And experimental studies indicate that certain components of dairy products, particularly glycomacropeptide (GMP) and G600 milk fat extract (G600), seem...

2012-01-10 15:15:00

ISELIN, N.J., Jan. 10, 2012 /PRNewswire/ -- Pharmos Corporation (OTC-PINK: PARS) announced today the dosing of the first patients in the US using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. This phase 2a proof-of-concept trial is being conducted at the Duke Clinical Research Unit of Duke University and the principal investigator is John Sundy, MD, PhD an expert in the treatment of gout. The trial is designed to assess the safety and...

2012-01-06 07:00:00

EAST BRUNSWICK, N.J., Jan. 6, 2012 /PRNewswire/ --Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that a product-specific billing code, or permanent J-code, for KRYSTEXXA® (pegloticase) became available on January 1, 2012. The new J-code, J2507, was assigned by the Centers for Medicare and Medicaid Services (CMS) and will help simplify the billing and reimbursement process for prescribers of KRYSTEXXA, the first and only U.S. Food and Drug Administration (FDA)...

2012-01-05 12:04:52

Drug appears to be well tolerated by patients A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial–the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares–show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events...

2011-12-08 07:30:00

HAYWARD, Calif., Dec. 8, 2011 /PRNewswire/ -- Metabolex today announced positive results from its clinical study of arhalofenate in combination with febuxostat (Uloric(TM), Takeda Pharmaceutical Company Limited). A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid (sUA). In the US, the goal of treatment is to reduce sUA levels to below 6 mg/dL. However, patients with severe tophaceous gout would...

2011-11-29 07:30:00

HAYWARD, Calif., Nov. 29, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that its arhalofenate program has been recognized in Windhover's "Top 10 most interesting cardiovascular/metabolic diseases projects to watch." Arhalofenate is a potential best-in-class treatment for gout that not only treats the hyperuricemia that causes gout, but also addresses...

2011-11-22 08:33:00

TARRYTOWN, N.Y., Nov. 22, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy. Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA is ten months from...